Wall Street analysts expect Orthopediatrics Corp (NASDAQ:KIDS) to announce earnings of ($0.09) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Orthopediatrics’ earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.07). Orthopediatrics reported earnings per share of ($0.21) during the same quarter last year, which would suggest a positive year-over-year growth rate of 57.1%. The company is expected to issue its next earnings results on Wednesday, August 14th.

According to Zacks, analysts expect that Orthopediatrics will report full-year earnings of ($0.45) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.40). For the next financial year, analysts expect that the company will post earnings of ($0.17) per share, with EPS estimates ranging from ($0.20) to ($0.13). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Orthopediatrics.

Orthopediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.04). The company had revenue of $14.66 million during the quarter, compared to analyst estimates of $14.67 million. Orthopediatrics had a negative net margin of 16.71% and a negative return on equity of 16.43%.

Several equities analysts recently issued reports on KIDS shares. BTIG Research restated a “buy” rating and issued a $44.00 price target on shares of Orthopediatrics in a research report on Friday, May 10th. BidaskClub upgraded Orthopediatrics from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. Zacks Investment Research upgraded Orthopediatrics from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Saturday, March 16th. Finally, JMP Securities started coverage on Orthopediatrics in a research report on Wednesday, February 20th. They issued an “outperform” rating and a $44.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $41.00.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pura Vida Investments LLC increased its position in Orthopediatrics by 15.9% during the 4th quarter. Pura Vida Investments LLC now owns 116,831 shares of the company’s stock worth $4,075,000 after purchasing an additional 15,997 shares during the period. Rhumbline Advisers increased its position in Orthopediatrics by 55.5% during the 4th quarter. Rhumbline Advisers now owns 8,770 shares of the company’s stock worth $306,000 after purchasing an additional 3,129 shares during the period. JPMorgan Chase & Co. increased its position in Orthopediatrics by 20.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 70,225 shares of the company’s stock worth $2,573,000 after purchasing an additional 11,931 shares during the period. Bank of Montreal Can increased its position in Orthopediatrics by 4,156.3% during the 4th quarter. Bank of Montreal Can now owns 2,043 shares of the company’s stock worth $71,000 after purchasing an additional 1,995 shares during the period. Finally, Royce & Associates LP increased its position in Orthopediatrics by 7.2% during the 4th quarter. Royce & Associates LP now owns 193,500 shares of the company’s stock worth $6,749,000 after purchasing an additional 13,000 shares during the period. Institutional investors own 45.03% of the company’s stock.

KIDS stock traded down $1.02 during trading on Tuesday, hitting $40.10. The company had a trading volume of 75,534 shares, compared to its average volume of 71,377. The stock has a market capitalization of $588.59 million, a PE ratio of -41.77 and a beta of 0.04. Orthopediatrics has a 1-year low of $18.77 and a 1-year high of $47.82. The company has a quick ratio of 7.77, a current ratio of 8.60 and a debt-to-equity ratio of 0.26.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

Read More: Liquidity

Get a free copy of the Zacks research report on Orthopediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthopediatrics (NASDAQ:KIDS)

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.